MedTrace Logo

Evaluation of TK3 in Improving Quality of Life in Patients With Malignancy Under Chemotherapy

NCT01168206 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2011-09-09

No results posted yet for this study

Summary

The association of nutritional supplement TK3 to conventional treatment of cancer patients reduces the intensity and frequency of toxic effects and side effects caused by adjuvant or palliative treatments for the protection of healthy tissues, resulting in a better quality of life.

Conditions

Interventions

DIETARY_SUPPLEMENT

TK3

Tritofano 160mg / Timina140mg and starch 150 mg

DIETARY_SUPPLEMENT

1 capsule, 3 times per day

Placebo

Sponsors & Collaborators

  • Lavilabor Natural Products Ltd

    lead INDUSTRY

Principal Investigators

  • Nilson Bruno Evangelista, Doctor · Lavilabor Natural Products Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-12-31
Completion
2012-08-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01168206 on ClinicalTrials.gov